Every 10-Q that PTC Therapeutics, Inc. (PTCT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PTCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PTCT filings page.
PTC Therapeutics, Inc. reported strong Q2 2026 results, with total revenues of $360.5 million, up from $178.9 million a year earlier. Growth was driven by net product revenue of $238.8 million and collaboration and license revenue of $50.6 million, including a $50.0 million milestone from Novartis for Huntington’s disease candidate votoplam. Royalty revenue contributed $71.1 million. Operating income reached $149.0 million and net income attributable to common stockholders was $83.5 million, or diluted EPS of $0.92, versus a prior-year loss.
PTC ended June 30, 2026 with $1.05 billion in cash and cash equivalents and $1.18 billion in marketable securities, against roughly $591 million of debt and a $2.32 billion liability for sale of future Evrysdi royalties, leaving stockholders’ deficit at $165.4 million. In June it issued $550.0 million of 0% convertible senior notes due 2031 and repurchased $222.0 million of its 1.50% notes due 2026, leaving $55.5 million outstanding. Operationally, Sephience for PKU is now approved in the U.S., EU, Japan, Brazil and additional geographies; Novartis commenced a global Phase 3 votoplam trial; PTC initiated a Phase 1 study of PTC612, plans a Phase 2a study of PTC844 and expects to start the PROVE-FA study of vatiquinone in Q3 2026. The company expects product cash flows, Novartis milestones and existing liquidity to fund operations for at least 12 months.
PTC Therapeutics reports Q1 2026 results showing solid product growth but a small loss. Total revenues were $272.6 million, down from $1.18 billion a year earlier when a large Novartis upfront payment boosted collaboration revenue. Net product revenue grew to $225.6 million, led by Sephience for PKU and DMD therapies Translarna and Emflaza, while royalty revenue from Evrysdi and other partnered products reached $46.8 million. The quarter showed an operating profit of $45.0 million, but after $49.0 million of net interest expense, mainly from the royalty financing and convertible notes, PTC recorded a net loss of $2.8 million. Cash, cash equivalents and marketable securities totaled about $1.89 billion, and management believes this, together with product sales and Novartis milestones, will fund operations for at least twelve months. The filing also highlights progress across rare‑disease programs, including global launches of Sephience, the Phase 3 votoplam program for Huntington’s disease now led by Novartis, and ongoing regulatory work on vatiquinone for Friedreich’s ataxia.
PTC Therapeutics (PTCT) filed its Q3 2025 10‑Q, reporting a return to profitability for the quarter and sharply higher year‑to‑date results. Q3 revenue was $211.0 million (vs. $196.8 million a year ago), and net income was $15.9 million (vs. a $106.7 million loss). Diluted EPS was $0.20.
For the first nine months, revenue reached $1.566 billion (vs. $593.6 million), driven by $998.4 million of collaboration and license revenue tied to the Novartis votoplam agreement, with net income of $817.6 million. Cash and cash equivalents were $672.6 million and marketable securities $1.015 billion. The stockholders’ deficit narrowed to $(155.8) million from $(1.10) billion at year‑end.
Product and pipeline updates include FDA approval of Sephience for PKU in July 2025 (and EC authorization in June 2025), EC non‑renewal of Translarna in March 2025 with certain EU country exceptions, and FDA acceptance of the resubmitted Translarna NDA in October 2024. The FDA approved the AADC gene therapy in the U.S. in November 2024 (marketed as Kebilidi). The FDA issued a complete response letter for vatiquinone in August 2025. The Novartis votoplam deal closed in January 2025 with a $1.0 billion upfront payment.